Tag: AF symposium 2026
J&J presents early outcomes from OMNY-AF pilot study alongside new Varipulse...
Johnson & Johnson (J&J) has announced 12-month pilot-phase data from the OMNY-AF study evaluating its investigational Omnypulse platform for the treatment of symptomatic paroxysmal...
Volta Medical’s RESTART trial provides “promising findings” on AI solutions in...
Volta Medical has announced results from the RESTART trial, published in the journal Heart Rhythm, that demonstrate positive outcomes for patients with recurrent atrial fibrillation...